Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Non-Hodgkin 24Lymphoma, Follicular 17Lymphoma 14Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, B-Cell 9Neoplasms 5Lymphoma, B-Cell, Marginal Zone 4Melanoma 3Leukemia 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Leukemia, B-Cell 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Tumor Lysis Syndrome 1Solid Cancers 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Oncology Patients Receiving Chemotherapy 1Neoplasm Metastasis 1Mesothelioma 1Mature B-cell Malignancies 1

Interventions

10-propargyl-10-deazaaminopterin 12Cyclophosphamide 8Prednisone 7belinostat 6Vincristine 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Doxorubicin 6Brentuximab Vedotin 5romidepsin 4mogamulizumab 4darinaparsin 4Vitamin B 12 4Gemcitabine 4Folic Acid 4selinexor 3denileukin diftitox 3Nivolumab 3Injections 3Bendamustine Hydrochloride 3tislelizumab 2tipifarnib 2tenalisib 2duvelisib 2Rituximab 2Lenalidomide 2HBI-8000 2Fenretinide 2E7777 fusion protein 2AFM13 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell, Peripheral × obinutuzumab × Clear all
NCT01644253 2021-05-20

Phase 1b Safety and Efficacy Study of TRU-016

Aptevo Therapeutics

Phase 1 Terminated
87 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡